We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
Cap. Flow
-$196M
Cap. Flow %
-4.5%
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$183M
2
ARGX icon
argenx
ARGX
+$128M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$108M
4
JNJ icon
Johnson & Johnson
JNJ
+$97.3M
5
HUM icon
Humana
HUM
+$95M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$194M
2
BAX icon
Baxter International
BAX
+$149M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$146M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$115M
5
ABBV icon
AbbVie
ABBV
+$109M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Financials 0.54%
3 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNAB
76
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.94M 0.04%
200,000
– –
DNAD
77
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.94M 0.04%
200,000
– –
SCYX icon
78
SCYNEXIS
SCYX
$36.1M
$1.78M 0.04%
119,941
+51,936
+76% +$1,000K
WGS icon
79
GeneDx Holdings
WGS
$1.81B
$1.2M 0.03%
28,788
– –
SNCE
80
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$864K 0.02%
21,500
– –
NUVB.WS
81
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$28K ﹤0.01%
99,999
– –
MSACW
82
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$10K ﹤0.01%
57,770
– –
ACET icon
83
Adicet Bio
ACET
$76.3M
– –
-195,000
Closed -$62.3M
AXSM icon
84
Axsome Therapeutics
AXSM
$12.4B
– –
-711,000
Closed -$29.4M
BAX icon
85
Baxter International
BAX
$12B
– –
-1,915,500
Closed -$149M
BHC icon
86
Bausch Health
BHC
$1.7B
– –
-1,694,700
Closed -$38.7M
BPMC
87
DELISTED
Blueprint Medicines
BPMC
– –
-291,184
Closed -$18.6M
EW icon
88
Edwards Lifesciences
EW
$48B
– –
-440,000
Closed -$51.8M
LKFT
89
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.85B
– –
-215,000
Closed -$13.3M
INSM icon
90
Insmed
INSM
$22.9B
– –
-1,354,539
Closed -$31.8M
ISRG icon
91
Intuitive Surgical
ISRG
$127B
– –
-325,000
Closed -$98M
MLTX icon
92
MoonLake Immunotherapeutics
MLTX
$1.66B
– –
-400,000
Closed -$4.44M
MRK icon
93
Merck
MRK
$324B
– –
-2,370,000
Closed -$194M
PEN icon
94
Penumbra
PEN
$12.6B
– –
-104,000
Closed -$23.1M
RCUS icon
95
Arcus Biosciences
RCUS
$3.52B
– –
-912,000
Closed -$28.8M
SNTI icon
96
Senti Biosciences Holdings
SNTI
$11.7M
– –
-50,000
Closed -$4.93M
VRDN icon
97
Viridian Therapeutics
VRDN
$2.19B
– –
-1,040,000
Closed -$19.2M
XNTK icon
98
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
– –
-3,300,000
Closed -$297M
GRTS
99
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-560,000
Closed -$2.31M
MRTX
100
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-1,393,000
Closed -$115M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2022 Portfolio in Review

As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management withdrew a net $196M in Q2 2022, closing 20 positions and reducing 13 holdings. Its most notable exit was Merck, an estimated $194M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Financials and Technology.

Against the trend, Avidity Partners Management opened a new position in Eli Lilly worth $198M.

  • Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
  • Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
  • Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
  • Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
  • Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
  • Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.